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Reactive oxygen species (ROS) participate in normal
intracellular signalling and in many diseases including
cancer and aging, although the associated mechanisms are
not fully understood. Forkhead Box O (FoxO) 3 transcrip-
tion factor regulates levels of ROS concentrations, and is
essential for maintenance of hematopoietic stem cells.
Here, we show that loss of Foxo3 causes a myeloprolifera-
tive syndrome with splenomegaly and increased hemato-
poietic progenitors (HPs) that are hypersensitive to
cytokines. These mutant HPs contain increased ROS,
overactive intracellular signalling through the AKT/mam-
malian target of rapamycin signalling pathway and rela-
tive deficiency of Lnk, a negative regulator of cytokine
receptor signalling. In vivo treatment with ROS scavenger
N-acetyl-cysteine corrects these biochemical abnormalities
and relieves the myeloproliferation. Moreover, enforced
expression of Lnk by retroviral transfer corrects the ab-
normal expansion of Foxo3/ HPs in vivo. Our combined
results show that loss of Foxo3 causes increased ROS
accumulation in HPs. In turn, this inhibits Lnk expression
that contributes to exaggerated cytokine responses that
lead to myeloproliferation. Our findings could explain the
mechanisms by which mutations that alter Foxo3 function
induce malignancy. More generally, the work illustrates
how deregulated ROS may contribute to malignant
progression.
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Introduction
Oxidative stress, broadly defined as an imbalance between
generation and detoxification of reactive oxygen species
(ROS), is deleterious to cells and implicated in a number
of degenerative diseases and malignancies (reviewed in
Beckman and Ames, 1998). In addition, excess accumulation
of ROS impacts cellular aging, whereas the ability to resist
oxidative stress is associated with evolutionary conserved
enhanced longevity (Beckman and Ames, 1998). Although
ROS are considered to be toxic byproducts of cellular
metabolism, increasing evidence support the notion that
ROS have a critical role in normal cellular signalling. In
particular, ROS are generated by cytokine signalling and
impact the function of a rapidly expanding list of numerous
effectors (reviewed in Thannickal and Fanburg, 2000). How
these activities affect normal and pathological physiology is
not fully understood.
ROS are particularly deleterious to hematopoietic stem cells,
specifically as they age (Ito et al, 2004; Miyamoto et al, 2007;
Tothova et al, 2007; Yalcin et al, 2008; and reviewed in
Ghaffari, 2008). A tightly controlled balance between hema-
topoietic stem and progenitor cell compartments maintains
normal blood cell homeostasis throughout life. Alterations
of this balance result in various disorders including leukae-
mias or bone marrow failure. For instance, myeloproliferative
disorders are a group of hematopoietic malignancies whose
incidence increase with age, exhibit enhanced proliferation
and survival of one or more myeloid lineage cells that arises
from an unbalanced expansion of hematopoietic myeloid
progenitor cells (Tefferi and Gilliland, 2007).
The Forkhead FoxO family of transcription factors are
critical regulators of oxidative stress and exert this function
at least partly by upregulating the expression of several anti-
oxidant enzymes (Kops et al, 2002; Nemoto and Finkel, 2002;
Murphy et al, 2003; Marinkovic et al, 2007; Tothova et al,
2007; Yalcin et al, 2008). FoxO1, FoxO3 and FoxO4 are wildly
expressed while FoxO6 is predominantly expressed in neuro-
nal tissues. Loss of a single FoxO leads to distinct phenotypes
in mice, underscoring their diverse non-redundant functions
in vivo (Castrillon et al, 2003; Hosaka et al, 2004). In
particular, female Foxo3-deficient mice exhibit a premature
infertility associated with ovarian follicle depletion early on
in life (Castrillon et al, 2003; Hosaka et al, 2004). In addition,
both Foxo3/ hematopoietic stem and erythroid cell
compartments exhibit enhanced susceptibility to oxidative
stress (Marinkovic et al, 2007; Miyamoto et al, 2007; Yalcin
et al, 2008).
FoxOs also regulate cellular responses to genotoxic stress,
consistent with a tumour suppressor function (Paik et al,
2007). In response to stress such as DNA damage or oxidative
stress, FoxOs induce cell cycle arrest, repair damaged DNA or
initiate apoptosis by modulating genes that control these
processes (Brunet et al, 1999; Dijkers et al, 2000; Medema
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et al, 2000; Nakamura et al, 2000; Tran et al, 2002; Alvarez
et al, 2003; Ghaffari et al, 2003; Marinkovic et al, 2007; Yalcin
et al, 2008). FoxO genes are also found at chromosomal
breakpoints in certain cancers, including acute myeloid
leukaemias (FoxO3 and FoxO4) (Borkhardt et al, 1997;
Hillion et al, 1997). Moreover, FoxO3 regulates the expression
and activity of ataxia telangiectasia-mutated protein kinase,
suggesting an important role in the maintenance of genomic
stability (Tsai et al, 2008; Yalcin et al, 2008).
Function of FoxO is restrained primarily by the phosphoi-
nositide-3-kinase (PI3-kinase)/AKTsignalling pathway (Biggs
et al, 1999; Brunet et al, 1999; Dijkers et al, 2000; Kashii et al,
2000; Nakae et al, 1999; Rena et al, 1999; Tang et al, 1999;
and reviewed in Greer and Brunet, 2008). The AKT serine
threonine protein kinase regulates a wide range of metabolic
processes through phosphorylation of numerous effectors,
including FoxO and mammalian target of rapamycin (mTOR)
(Gingras et al, 1998; Brunet et al, 1999; Inoki et al, 2002;
Manning et al, 2002) a kinase that stimulates cell growth and
proliferation through multiple effectors including ribosomal
S6 kinase (S6K1) and the eukaryotic initiation factor 4E-
binding protein.
In response to cytokines, growth factors or oncoproteins,
activated AKT kinase directly phosphorylates FoxO on three
conserved residues, resulting in their nuclear exclusion and
subsequent degradation (Biggs et al, 1999; Brunet et al, 1999;
Matsuzaki et al, 2003; Plas and Thompson, 2003; Hu et al,
2004). In contrast, stress stimuli, or inhibition of PI3-kinase/
AKT signalling pathway by growth factor/cytokine withdra-
wal, induce FoxO’s nuclear localization, thereby enhancing
their transcriptional activity (Essers et al, 2004; Lehtinen
et al, 2006; van der Horst et al, 2006). The PI3-kinase/AKT
signalling pathway is activated in numerous human and
animal malignancies, although how this contributes to the
pathogenesis of these diseases is not entirely clear (Ugo et al,
2004; Bellacosa et al, 2005; Dai et al, 2005; Yilmaz et al, 2006;
Zhang et al, 2006). In addition to AKT, a number of kinases
regulate the activity of FoxO both positively and negatively.
In addition to phosphorylation, FoxO proteins are subject
of several other post-translational modifications such as
acetylation, methylation and ubiquitination whose combined
integrated signals determine the activity of FoxOs.
Recent findings have established a critical function for
FoxO family members in the regulation of normal and
malignant hematopoietic stem cell activity (Miyamoto et al,
2007; Tothova et al, 2007; Yalcin et al, 2008; Naka et al, 2010).
In particular, Foxo3’s suppression of ROS is essential for the
maintenance of hematopoietic stem cell quiescence and
homeostasis (Miyamoto et al, 2007; Yalcin et al, 2008). In
addition, abnormal repression of Foxo3 has been implicated
in the pathogenesis of myeloproliferative disorders and other
haematological malignancies (Ghaffari et al, 2003; Komatsu
et al, 2003; Fernandez de Mattos et al, 2004; Essafi et al,
2005). Despite these findings, of the entire scope of Foxo3
functions, regulation of hematopoietic progenitors (HPs) is
not fully defined (Miyamoto et al, 2007; Yalcin et al, 2008).
Here, we show that loss of Foxo3 results in a myeloproli-
ferative syndrome in mice. We further demonstrate that
increased ROS accumulation in Foxo3/ primitive myeloid
progenitors activates the cytokine-induced AKT/mTOR
signalling pathway and expands Foxo3-deficient primitive
myeloid progenitors. Accordingly, this myeloproliferative
syndrome is ameliorated by systemic administration of ROS
scavengers. Moreover, Lnk (SH2B3), a negative regulator of
cytokine signalling, is directly implicated in this process. Our
combined data indicate that Foxo3 modulates HP homeo-
stasis by controlling cytokine-dependent production of, and
response to, ROS. These cumulative findings illustrate new
mechanisms through which deregulated ROS could contri-
bute to the development of malignancies.
Results
Foxo3/ mice exhibit a myeloproliferative syndrome
Foxo3/ mice display increased white blood cell counts,
with an increased circulating neutrophils (Po0.03) and
monocytes (Po0.01), and a concomitant reduction of circu-
lating lymphocytes (Po0.005) and red blood cells (Table I;
Marinkovic et al, 2007). These anomalies of the peripheral
blood are associated with myeloproliferative syndrome
(Figure 1). Foxo3-deficient mice exhibit an enlarged spleen
(Figure 1A), increased number of splenocytes (Figure 1B)
and extramedullary hematopoiesis (Figure 1C, D and E,
Supplementary Figure 1A), with increased frequency of
erythrocytic and granulocytic lineages (Supplementary
Figure 1). Concomitantly, the bone marrow is hypocellular
(Figure 1B) with decreased production of mature B and
erythroid cells (Figure 1D; Supplementary Figure 1;
Marinkovic et al, 2007). Histopathology analysis corrobo-
rated these findings, showing increased extramedullary
hematopoiesis containing erythroid and myeloid cells in
the spleen and liver of Foxo3/ mice (Figure 1A and
Supplementary Figure 2).
In agreement with a myeloproliferative syndrome, the
myeloid progenitor compartment is significantly enhanced
in the bone marrow, spleen and peripheral blood of Foxo3-
deficient mice (Figure 2A and Supplementary Figure 3).
In particular, myeloid colony-forming unit-granulocyte-
macrophage-derived colonies are increased in numbers and
size (Supplementary Figure 3 and data not shown).
Similarly, the size of primitive myeloid progenitor pool
was enhanced in Foxo3/ bone marrow (Figure 2B). The
compartment of colony-forming-spleen day 12 (CFU-Sd12)-
derived colonies was also increased (Po0.002; Figure 2C),
further supporting an expansion of the early myeloid pro-
genitors. In addition, Foxo3/ HP cells were overly sensitive
to cytokines (Figure 2D) and generated significantly larger-
size colonies in vitro (Supplementary Figure 3 and data not
shown), which are the hallmarks of myeloproliferative
disorders (Ghaffari et al, 1999; Levine and Gilliland, 2008).
Table I Comparison of blood parameters of Foxo3+/+ and
Foxo3/ mice
Parameters Foxo3+/+ Foxo3/ P-value
WBC ( 1000/ml) 9.45±1.13 13.48±1.16 0.01
Neutrophils (%) 8.98±1.66 13.80±1.76 0.03
Lymphocytes (%) 83.69±1.98 75.55±2.09 0.005
Monocytes (%) 2.98±0.58 6.87±1.59 0.01
Eosinophils (%) 2.70±0.25 2.33±0,39 0.21
Basophils (%) 1.34±0.32 0.95±0.09 0.14
Results for wild type (n¼ 10) and Foxo3/ (n¼ 21) blood are
shown as mean±s.e.m. The analyses are from at least three
independent experiments.
Foxo3/ myeloproliferation by ROS via AKT/mTOR
S Yalcin et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 24 | 2010 4119
These data suggest that Foxo3 suppresses HP production and
proliferation by inhibiting cytokine signalling. These findings
were surprising, as Foxo3/ hematopoietic stem cells are not
highly cycling in vivo and do not generate excessive number
of HPs in culture (Yalcin et al, 2008), suggesting that these
observations were not simply the result of a highly prolifera-
tive hematopoietic stem cell compartment in Foxo3/ mice.
ROS-mediated amplification of AKT/mTOR signalling
pathway enhances primitive HP compartment in
Foxo3/ mice
Foxo3 suppresses ROS in many cell types, including in
hematopoietic cells, by regulating a programme of anti-oxi-
dant gene expression (Kops et al, 1999; Nemoto and Finkel,
2002; Marinkovic et al, 2007; Miyamoto et al, 2007; Yalcin
et al, 2008). Accordingly, Foxo3-mutant lineage-negative
bone marrow cells exhibited reduced expression of several
anti-oxidant enzyme genes (Supplementary Figure 4). In
addition, ROS were significantly overaccumulated in different
Foxo3/ subpopulations of lineage-negative cells enriched
for myeloid progenitors (Figure 3 and Supplementary Figure
5). ROS concentrations were highly enhanced (approximately
1.6-fold, Po0.02; Figure 3) in Foxo3/ Lin IL7Ra Sca-1
c-Kitþ cells, a population that encompasses all myeloid
progenitors (Akashi et al, 2000), and increased significantly
in freshly isolated Foxo3/ common myeloid progenitors
(CMP), as compared with their wild-type counterparts (ap-
proximately 1.2-fold, Po0.03; Supplementary Figure 5). CMP
is a highly pure population of hematopoietic cells giving rise
to megakaryocyte/erythrocyte and granulocyte/monocyte
progenitors (Akashi et al, 2000). Similar results were ob-
tained from analysis of ROS accumulation in total Foxo3-
deficient bone marrow depleted from lineage-restricted cells
(data not shown). In vivo treatment of mice with ROS
scavenger N-acetyl-cysteine (NAC, 100 mg/kg), normalized
the levels of ROS in Foxo3/ Lin IL7Ra Sca-1 c-Kitþ cell
population (Figure 3), supporting the specificity of ROS
measurement. Interestingly, these experiments revealed
two distinct populations of ROS-containing cells (ROS-high
or ROS-hi and ROS-low) in primitive myeloid progenitors of
both wild-type and Foxo3/ origin. The significant increase
of ROS observed in Foxo3/ Lin IL7Ra Sca-1 c-Kitþ cell
population was entirely in ROS-hi fraction (Figure 3). This
ROS-hi subpopulation may be the one that elicits cellular
responses, such as increased cell cycle or apoptosis, to
oxidative stress in primitive myeloid progenitors.
To investigate the mechanisms of enhanced myeloproli-
feration caused by loss of Foxo3, we interrogated cytokine-
mediated activation of principal signalling pathways in
bone-marrow-derived HPs. Freshly isolated bone marrow
cells were depleted of mature lineages by immunoselection
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Figure 1 Myeloproliferative-like syndrome in Foxo3/mice. (A) Representative whole-mount (upper panels) and histological sections (lower
panels) of spleens from 11-week-old wild-type (þ /þ ) and Foxo3/ (/) mice. Increased extramedullary myeloid hematopoiesis in the red
pulp and minimal depletion of marginal zone lymphocytes with the retention of the T-cell regions in Foxo3/ spleen, as compared with the
wild-type are shown. (B) Total number of bone marrow (n¼ 32) and spleen cells (n¼ 12) is shown, Student’s t-test. (C) Representative FACS
plots of FSC versus SSC of bone marrow, spleen and blood of wild-type and Foxo3/ mice are shown. Percentages of FSChighSSChigh
(granulocytic) cells are marked. (D) Total number of bone marrow cells in each lineage is plotted. Total number of bone marrow erythroid (TER
119, n¼ 11), B (B220, n¼ 14) and Tcells (CD3, n¼ 11) and neutrophils (Gr-1/Mac-1, n¼ 11) is shown. (E) Total number of cells in each lineage
of the spleen, TER 119 (n¼ 8), B220 (n¼ 8), CD3 (n¼ 11) and Gr-1/Mac-1 (n¼ 11) (Student’s t-test). The analyses are from at least four
independent experiments.
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stimulation with interleukin-3 (IL-3). Myeloid progenitors
constitute a significant majority of Lin cells expressing IL-3
receptor at the steady state. To our surprise, IL-3 stimulation
of Foxo3/ Lin cells led to hyperphosphorylation of AKT,
mTOR and mTOR substrate S6K1 (Figure 4A). In contrast,
STAT5 proteins, another effector of IL3 signalling, were not
affected in these cells (Figure 4A). Similar results showing
specific hyperactivation of the AKT/mTOR pathway in
Foxo3/ cells were obtained with other cytokines such
as erythropoietin (Epo, data not shown). In agreement with
in vivo overactivation of AKT/mTOR signalling pathway
mediating enhanced generation of early myeloid progenitors
in Foxo3/ mice, in vivo administration of the mTOR
inhibitor rapamycin resulted in significant reduction of
Foxo3/-derived CFU-Sd12, as compared with controls in
lethally irradiated hosts (Figure 4B).
Normal cytokine signalling, including signalling by IL-3
(Sattler et al, 1999), is mediated in part by ROS in in vitro
cultured cells (Thannickal and Fanburg, 2000; Finkel, 2003).
Thus, we investigated whether abnormal increase of ROS
contributes to the hyperactivation of AKT/mTOR signalling
pathway caused by loss of Foxo3 in primary cells in vivo. We
treated mice with the ROS scavenger NAC (100 mg/kg), and
tested IL-3 signalling responses by examining phosphoryla-
tion of downstream targets AKT, mTOR and S6K1
(Figure 4A). In vivo treatment with NAC specifically reduced
the intensity of IL-3-mediated phosphorylation of AKT and
mTOR in Foxo3-mutant cells enriched for HPs. Surprisingly,
reduction in phospho-mTOR in response to NAC did not
impact phosphorylation of the mTOR target S6K1 in Foxo3
mutants, as compared with normal hematopoietic cells
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Figure 2 Enhanced hematopoietic progenitor activity in Foxo3/ mice. (A) Progenitor-derived colonies were measured in the bone marrow,
spleen and blood of wild-type and Foxo3/ mice. The analyses are from four independent experiments in each of which two to three animals
were either pooled or analysed independently. (B) Frequency (left panel) of highly enriched myeloid progenitor Lin IL7Ra Sca-1 c-Kitþ
compartment (right panel) in wild-type and Foxo3/ bone marrow is shown (n¼ 5 in each group, Student’s t-test). The frequency of Sca-1
c-Kitþ cells within Lin IL7Ra-gated cells is shown (the frequency of Lin IL7Ra Sca-1 c-Kitþ cells within bone marrow is 1.3±0.11% for
wild type and 2.2±0.2% for Foxo3/). One representative of three independent experiments is shown. (C) CFU-S-derived colonies formed in
the spleen were measured 12 days after in vivo injection of 105 wild-type or Foxo3/ bone marrow cells into lethally irradiated hosts;
representative of two independent experiments, n¼ 5 in each group is shown, Student’s t-test. (D) Colony-forming cell ability of wild-type and
Foxo3/ progenitors was measured after plating 105 cells in semi-solid methylcellulose cultures in three replicates in the presence of limiting
doses of the indicated cytokines (colonies of 20 or more cells were counted after 8 days and the numbers of colonies present at each cytokine
concentration were calculated as percentages of the number formed in the highest concentration of the indicated cytokine). Meanþ s.e.m. of
three independent experiments, each pool of two to three mice. Student’s t-test; *Po0.05, **Po0.01.
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Figure 3 Enhanced ROS accumulation in Foxo3/ primitive mye-
loid progenitors. Representative FACS profile of bone marrow Lin
IL7Ra Sca-1 c-Kitþ that contain 98% of all myeloid progenitor
cells (Akashi et al, 2000) (left panel). Frequency of c-Kitþ Sca1
cells within Lin IL7Ra cells is shown. Endogenous ROS concen-
trations were measured in freshly isolated Lin IL7Ra Sca-1
c-Kitþ cells (right panel) from wild-type or Foxo3/ mice treated
daily in vivo with NAC (100 mg/kg) or PBS for 15 days; fold change
in mean fluorescence intensity (MFI) of ROS in gated subpopula-
tions (ROS-hi using - - - - - - - gate), as compared with control
wild-type cells treated with PBS is shown as mean±s.e.m., n¼ 3;
Student’s t-test. One of two independent experiments is shown.
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response to NAC in Foxo3-mutant cells is not clear, it is
possible that the residual pmTOR kinase activity, despite
the presence of NAC (Figure 4A, lanes 11 and 12), is sufficient
for phosphorylation of S6K1 to the same extent as controls,
especially if the activity of a phospho-S6K1-specific phospha-
tase is reduced in Foxo3/ cells. NAC treatment did not alter
STAT5 activity, as determined by phosphorylation on tyrosine
694 or serine 726 (Figure 4A).
Interestingly, NAC treatment specifically attenuated IL-3-
mediated phosphorylation of AKT and S6K1 in wild-type HPs
(Figure 4A), suggesting that ROS participate in specific
cytokine signalling pathways in primary bone marrow cells
in vivo. Next, we asked whether this data remains valid in
populations of lineage-negative bone marrow cells that
contain all myeloid but not lymphoid progenitors. We
found that AKT was hyperphosphorylated in response to
IL-3 in Foxo3/ myeloid (Lin IL7Ra Sca-1 c-Kitþ ) pro-
genitors, as measured by flow cytometric analysis of intra-
cellular pAKT (Figure 4C). NAC treatment reduced pAKT
significantly in this highly enriched population of myeloid
progenitors, in both wild-type and Foxo3/ mice (Figure 4C,
Supplementary Figure 6). As anticipated, in vivo treatment
with NAC reduced ROS concentrations significantly in
Foxo3/ Lin IL7Ra Sca-1 c-Kitþ bone marrow cells
(Figure 4C, right panel).
Importantly, and in agreement with the results above,
in vivo administration of NAC normalized the number and
the size of multipotential Foxo3/-derived CFU-Sd12 in leth-
ally irradiated hosts without any significant impact on wild-
type CFU-Sd12 (Po0.0003, n¼ 5; Figure 5). Taken together,
these results indicate that ROS specifically amplify cytokine-
mediated AKT/mTOR signalling pathway to stimulate the
expansion of HPs in Foxo3/ mice.
To investigate whether accumulation of ROS in myeloid
progenitors contributes to the pathogenesis of the myelopro-
liferative syndrome, we subjected wild-type and Foxo3-
deficient mice to a short, 15-day treatment with NAC.
Interestingly, in vivo NAC administration treated some of
the myeloproliferative symptoms in Foxo3-deficient mice
(Figure 6, Supplementary Figure 6). The in vivo treatment
with NAC normalized the total number of bone marrow and
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Figure 4 mTOR mediates the enhancement of Foxo3/ hematopoietic progenitor cell compartment. (A) Western blot analysis of phosphor-
ylation of signalling proteins in lineage-negative bone marrow cells isolated from wild-type and Foxo3/mice (n¼ 4). Mice were administered
daily with NAC (100 mg/kg) or PBS in vivo for 3 days, after which lineage-negative cells were isolated, serum- and cytokine starved for 2 h and
stimulated with IL-3 (20 ng/ml) for the indicated time points (0, 10 and 30 min) in vitro in the absence or presence of NAC (100mM) before
preparing the whole cell extract; representative immunoblot of three independent experiments is shown. (B) Number of CFU-Sd12-derived
colonies formed in the spleens of lethally irradiated mice reconstituted with 105 wild-type or Foxo3/ bone marrow cells detected after 12 days
during which mice were administered either rapamycin (Rapa; 4 mg/kg) or vehicle (Veh) intraperitoneally for 5 days a week. Results shown are
mean±s.e.m. (n¼ 5 in each group, Student’s t-test). One representative of three independent experiments is shown. Representative spleen
from each group is shown in the lower panel. (C) ROS levels (right panel) and phosphorylated AKT protein kinase (left panel) were measured
by FACS in Lin IL7Ra Sca-1 c-Kitþ bone marrow cells of wild-type and Foxo3/ mice treated daily with NAC or PBS for 2 weeks in vivo,
after which isolated cells were serum- and cytokine starved for 2 h and stimulated with IL-3 (20 ng/ml) in vitro for 10 min. Results
are mean±s.e.m. of percentage of Lin IL7Ra Sca-1 c-Kitþ bone marrow cells that express phosphoAKT (pAKT), as detected by FACS
(n¼ 6 in each group, Student’s t-test). Endogenous ROS-hi levels were measured in Lin IL7Ra Sca-1 c-Kitþ bone marrow cells of the
same mice as in the left panel, at the end of the 2 week in vivo treatment (right panel), and shown as fold change in MFI of experimental as
compared with control wild-type cells (n¼ 6 in each group, Student’s t-test). Animals were analysed individually. One of two independent
experiments is shown.
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also had a specific and significant effect on the frequency and
total number of immature myeloid (Mac-1/Gr-1 positive)
cells in the bone marrow without any impact on B cells
(Figure 6B and Supplementary Figure 6).
To identify the mechanism by which ROS regulate the
myeloproliferative syndrome, we asked whether ROS impact
the proliferation or apoptosis rate of Foxo3/ myeloid
progenitor cells. Thus, mice were treated in vivo with NAC
and the rate of 5-bromo-2-deoxyuridine (BrdU) incorporation
in Lin IL7Ra Sca-1 c-Kitþ cells was measured. We found
that Foxo3/ myeloid progenitors exhibit a highly and
significantly increased proliferation, as compared with their
wild-type counterparts (Figure 6C, top panel). This was not
accompanied by any modification of their apoptotic rate
(Figure 6C, bottom panel). NAC treatment significantly re-
duced the percentage of cycling Foxo3-deficient myeloid
progenitor cells (Figure 6C, top panel), without having
any effect on their apoptotic rate (Figure 6C, bottom panel).
ROS regulation of proliferation of Foxo3/ primitive myeloid
progenitor cells is in accord with our earlier findings of
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Figure 6 NAC treatment ameliorates myeloproliferative syndrome in Foxo3/ mice in vivo. (A) Mice were treated daily with NAC (100 mg/
kg) or PBS and their total number in the bone marrow and spleen was measured after 15 days (n¼ 3 in each group). (B) Frequency of myeloid
(Mac-1 and Gr-1 positive) and B (B220 positive) cells in the bone marrow of mice from A (n¼ 3 in each group). (C) Percentage of BrdU- (upper)
and annexin-V-binding positive (lower) cells in wild-type and Foxo3/ Lin IL7Ra Sca-1 c-Kitþ cells was analysed by flow cytometry after
15 days in vivo of NAC (100 mg/kg) or PBS treatment of mice from A (n¼ 3 in each group). (D) Wild-type or Foxo3/ mice were treated daily
with NAC (100 mg/kg) or PBS for 2 weeks after which bone marrow cells were isolated and injected (5105 cells) into lethally irradiated hosts
in the absence of any further treatment. CFU-S-derived colonies were counted in the hosts 12 days after cell injection, n¼ 5 in each group;
Student’s t-test. Representative spleen from each group is shown in the lower left panel. ROS-hi concentrations were measured in an aliquot of
Lin IL7Ra Sca-1 c-Kitþ cells isolated from each mouse 15 days after in vivo NAC or PBS treatment. ROS levels are shown as fold change in
MFI as compared to control wild type cells (bottom right panel). One representative of two independent experiments is shown.
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Figure 5 NAC treatment corrects the expansion of Foxo3/ primi-
tive multipotential hematopoietic progenitor compartment in vivo.
CFU-S-derived colonies were measured 12 days after injection of 105
wild-type or Foxo3/ bone marrow cells into lethally irradiated
hosts and treated daily with NAC (100 mg/kg) or PBS. One repre-
sentative of three independent experiments is shown (n¼ 5 in each
group, Student’s t-test). Representative spleen of each group is
shown in the bottom panel.
Foxo3/ myeloproliferation by ROS via AKT/mTOR
S Yalcin et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 24 | 2010 4123
in these cells (Figure 4). We further asked whether pretreat-
ment with NAC is sufficient to normalize the activity of
Foxo3/ primitive HPs in transplanted hosts in vivo. As
shown in Figure 6D, pretreatment of Foxo3/ mice with
NAC significantly decreased the number of multipotential
CFU-Sd12-derived colonies formed in the spleen of lethally
irradiated hosts (upper panel and lower left panel), likely
through reduction of the levels of ROS in primitive myeloid
progenitors (Figure 6D, bottom right panel). These results
strongly suggest that the myeloproliferation in Foxo3/mice
is mediated by ROS and is sensitive to NAC. Altogether, these
results indicate that the treatment with ROS scavenger NAC
improves, at least partially, the myeloproliferative phenotype
of Foxo3/ mice.
Lnk, a negative regulator of cytokine signalling, is
directly implicated in enhanced Foxo3/ primitive
HP cell activity
To further examine how Foxo3 regulates HP expansion, we
used real-time QRT–PCR to compare the expression of nu-
merous regulators of cytokine signalling in lineage-depleted
(Lin) cells from WT and Foxo3/ bone marrow. The
function of some of negative regulators is known to be
modulated by ROS (Thannickal and Fanburg, 2000); thus,
we initially focused on negative regulators. The expression of
most negative regulators of cytokine signalling was not
significantly affected by loss of Foxo3. These include protein
tyrosine phosphatase (SHP1, PTPN6) a negative regulator of
JAK2 signalling, suppressor of cytokine signalling 1, which
negatively regulates STATs, and PTEN, a negative regulator
of PI3-kinase/AKT signalling (Figure 7A). However, the
expression of SH2-containing inositol-5-phosphatase (SHIP),
another negative regulator of PI3-kinase signalling, was sig-
nificantly reduced. In addition, the expression of the adaptor
protein Lnk (SH2B3), a negative regulator of cytokine signal-
ling (Takaki et al, 2002; Velazquez et al, 2002; Tong and
Lodish, 2004; Tong et al, 2005), was significantly down-
regulated in Foxo3/ lineage-negative progenitors, as deter-
mined by QRT–PCR (Figure 7A) and confirmed by western
blot analysis (Figure 7B). Altered Lnk expression is due
to loss of Foxo3, as overexpression of Foxo3 in primitive
bone marrow cells significantly enhanced Lnk expression
(Figure 7C). Lnk (SH2B3) belongs to a family of SH2-containing
adaptor proteins, which also includes SH2-B1 and APS
(SH2B2) (Rudd, 2001). Expression of SH2-B1, which is a
positive regulator of cytokine signalling, was significantly
increased in Foxo3-mutant cells (Figure 7A). Thus, deregula-
tion of Lnk and SH2-B1 could contribute to the enhanced
cytokine responses observed in Foxo3/ progenitors.
Lnk-deficient mice exhibit a myeloproliferative-like dis-
order similar to what we observe here with loss of Foxo3
(Takaki et al, 2002; Velazquez et al, 2002). Thus, we asked
whether decreased expression of Lnk contributes to the
myeloproliferation observed in Foxo3-mutant mice. To
address this, mice were treated with high-dose 5-fluorouracil
(5-FU), which ablates proliferating hematopoietic cells (Suda
et al, 1983; Lemieux et al, 1995), and populations of bone
marrow mononuclear cells highly enriched for primitive
hematopoietic stem and progenitors were isolated and trans-
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Figure 7 Deregulated expression of modulators of cytokine signalling in Foxo3/ hematopoietic progenitor cells. (A) QRT–PCR expression
analysis of cytokine receptor signalling regulatory genes in lineage-negative wild-type and Foxo3/ cells. Quantification of target genes is
relative to b-actin. Results are mean±s.e.m. of duplicate analysis of at least three cDNAs, each generated from a pool of two to three wild-type
or Foxo3/mice; Student’s t-test. (B) Western blot analysis of endogenous Lnk protein in total bone marrow cells isolated from two wild-type
and two Foxo3/mice; representative immunoblot of three independent experiments is shown. (C) QRT–PCR analysis of Foxo3 (upper panel)
and Lnk (lower panel) expression in mononuclear cells derived from 5-FU-treated wild-type and Foxo3/ mice, transduced with MSCV-IRES-
GFP (MIG) vector control or MIG-Foxo3; results are mean±s.e.m. of three independent experiments.
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(MIG) alone or with MIG encoding for Lnk (MIG-Lnk). Forced
expression of Lnk (Figure 8A) was confirmed in an aliquot
of transduced GFP-positive wild-type or Foxo3/ primitive
hematopoietic cells (Figure 8B). Retrovirally transduced cells
from Figure 8A and B were injected into lethally irradiated
hosts and CFU-Sd12 were measured after 12 days. Ectopic
expression of Lnk in contrast to vector control normalized the
number of CFU-Sd12 derived from Foxo3-mutant mice de-
tected in lethally irradiated hosts (Figure 8C), indicating that
the relative loss of Lnk contributes to the overactivation of
the CFU-Sd12 compartment in Foxo3
/ mice. This is likely
by constraining cytokine-mediated hyperactivation of AKT/
mTOR signalling pathway, as ectopic expression of Lnk, but
not of vector control, in primitive Foxo3/ hematopoietic
cells reduced the phosphorylation of AKT, mTOR and the
S6K1-substrate S6 ribosomal protein in these cells in response
to IL-3 (Figure 8D, Supplementary Figure 7).
Foxo3 could regulate Lnk expression through a number of
different mechanisms. We could not detect any consensus
FoxO binding site in regulatory regions of mouse Lnk gene
that is conserved among mammals, suggesting the absence of
direct transcriptional effects. Therefore, we investigated
whether elevated ROS concentrations inhibit Lnk gene
expression. Thus, mice were treated with NAC (100 mg/kg)
or PBS for 3 days in vivo, and bone marrow myeloid
progenitors (Lin IL7Ra Sca-1 c-Kitþ ) were analysed for
Lnk expression. NAC treatment significantly increased the
expression of Lnk mRNA in Foxo3/ myeloid progenitors,
without having any impact on the expression levels of
SHIP or SHP1 (Figure 9A). In addition treatment with
NAC did not affect the expression of Lnk in wild-type cells.
This was confirmed by western blot analysis of Lnk
(Figure 9B). Consistent with these results, in vitro treatment






































































Wild type + MIG 
Wild type + MIG-Lnk 
Foxo3–/– + MIG
Foxo3–/– + MIG-Lnk
Wild type + MIG 




























Wild type + MIG 






Figure 8 Decreased expression of Lnk is critical for increased activity of primitive hematopoietic progenitor cell compartment in Foxo3-
deficient mice. (A) Flow cytometry profile of GFP expression in wild-type or Foxo3/ bone marrow lineage-negative cells derived from 5-FU-
treated mice and transduced with MIG encoding for Lnk (MIG-Lnk; FACS profile was almost identical with MIG vector control). (B) QRT–PCR
analysis of Lnk expression in FACS-sorted retrovirally transduced GFPþ gated cells from A; results are mean±s.e.m. of three independent
experiments; Student’s t-test (C) Number of CFU-S-derived colonies formed in the spleens of lethally irradiated hosts (n¼ 5 in each group)
reconstituted with 5-FU-treated bone marrow mononuclear cells transduced with retroviral vector MIG or MIG-Lnk. FACS-sorted GFP-positive
(3104)-transduced primitive hematopoietic wild-type or Foxo3/ cells (from A, B) were injected into lethally irradiated hosts and spleen
colonies were counted 12 days later. Results shown as mean±s.e.m. (n¼ 5 mice); Student’s t-test. Representative spleens are shown in the
lower panel. One representative of three independent experiments is shown. (D) Quantification of phosphorylated AKT, mTOR and S6 proteins
in mononuclear cells derived from 5-FU-treated wild-type or Foxo3/ mice transduced with MIG vector control or MIG-Lnk in response to
IL-3. The percentage of cells with phoshorylated AKT, mTOR or S6 proteins was measured in GFPþ gated cells. Results shown are mean of two
independent experiments.
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expression, although this effect was dependent on H2O2
concentration (Supplementary Figure 8). Given ROS-
mediated activation of mTOR signalling (Figure 4), the effect
of ROS on Lnk (Figure 9A, B and Supplementary Figure 8)
and the impact of Lnk on AKT/mTOR signalling (Figure 8D
and Supplementary Figure 7), we asked whether mTOR
signalling has any impact on the expression of Lnk. As
shown in Figure 9C, rapamycin treatment increased Lnk
expression in bone marrow cells to some extent, suggesting
that mTOR signalling participates in the regulation of Lnk
expression. The mTOR regulation of Lnk expression might be
through its control of ROS (Supplementary Figure 9). These
results suggest that intracellular ROS concentrations are
critical for the regulation of expression of the negative
regulator of cytokine signalling Lnk.
Discussion
Excessive ROS concentrations lead to abnormal proliferation,
growth and malignancies (Neumann et al, 2003; Ito et al,
2004). Here, we have identified deregulation of sensitivity of
cellular signalling to physiological ROS as an additional
mechanism by which ROS compromise normal growth and
lead to malignancies. Our key finding is that overaccumu-
lated ROS in Foxo3/ mice exert a critical role in expansion
of primitive HP cell compartment and the regulation of
myeloproliferation in these mice. We have shown that
Foxo3/ mice display a myeloproliferative syndrome char-
acterized by splenomegaly, abnormal enhanced production of
primitive HPs in hematopoietic organs, extramedullary he-
matopoiesis, high sensitivity of HPs to cytokines and signifi-
cant increase in the production of white blood cells. This
phenotype is reminiscent of myeloproliferative disorders and
suggests that Foxo3 has a role in these diseases. In addition,
sensitivity of the Foxo3/ myeloproliferative phenotype to
ROS scavenger NAC suggests that this compound may have
some effect in myeloproliferative diseases in general.
Overaccumulation of ROS is the principal mediator of
the amplification of Foxo3/ primitive HP pool, as ROS
scavenger NAC normalized the number of Foxo3/-derived
CFU-Sd12 and the cycling of Foxo3
/ primitive myeloid
progenitors, and ameliorated the myeloproliferative syndrome
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Figure 9 Regulation of Lnk expression is mediated by ROS in Foxo3/ primitive myeloid progenitor cells. (A) QRT–PCR gene expression
analysis of regulators of cytokine signalling in Lin IL7Ra Sca-1 c-Kitþ bone marrow cells from mice (n¼ 3) treated in vivo for 3 consecutive
days with NAC (100 mg/kg) or PBS. One representative of three independent experiments is shown. (B) Western blot analysis of endogenous
Lnk protein in total bone marrow cells isolated from wild-type and Foxo3/mice daily treated with NAC (100 mg/kg) or PBS in vivo for 3 days.
A representative immunoblot of two independent experiments is shown. (C) QRT–PCR analysis of Lnk expression in total bone marrow cells
isolated from wild-type and Foxo3/ mice and treated in vitro with rapamycin (2mM) or vehicle for 24 h (n¼ 3).
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hypothesize that potential DNA damage in ROS-hi subpopu-
lation (Figure 3) of Foxo3/ Lin IL7Ra Sca-1 c-Kitþ cells
may contribute to acquisition of growth-enhancing mutations
in this cell population, leading to malignant progression.
Our results suggest that ROS regulation of Lnk is an
integral part of balancing cytokine receptor signalling by
regulating their sensitivity to various modulations of physio-
logical ROS. Relative decrease of Lnk expression as a result of
loss of Foxo3 leads to enhanced AKT/mTOR signalling path-
way, increased cycling and expansion of Foxo3-mutant HP
cells (Figure 8D and Supplementary Figure 7). Several recent
reports establish a strong link between alteration of Lnk
expression and myeloproliferative syndromes in mouse and
man (Baran-Marszak et al, 2010; Bersenev et al, 2010; Oh
et al, 2010), further highlighting the potential importance of
ROS regulation of Lnk signalling pathway in understanding
the underlying mechanism of myeloproliferative syndromes.
ROS are generated by oncoproteins and several cytokine
and growth factor stimuli (Sundaresan et al, 1995;
Thannickal and Fanburg, 1995; Irani et al, 1997; Sattler
et al, 1999, 2000; Vafa et al, 2002; Zhu et al, 2006).
Although the exact mechanism of generation of ROS by
cytokine receptor signalling in non-phagocytic cells is not
known, it is believed that by modifying the function of many
signalling proteins, ROS participate in normal cellular signal-
ling and regulate cell proliferation (reviewed in Thannickal
and Fanburg, 2000; Ghaffari, 2008). Here, we have shown
that, in addition to its known targets such as tyrosine
phosphatase 1B (PTPB1, PTPN1) and PTEN (Hecht and
Zick, 1992; Barford et al, 1994; Barrett et al, 1999a, 1999b;
Meng et al, 2002, 2004; Savitsky and Finkel, 2002; Finkel,
2003; Seo et al, 2005), ROS regulate the expression of the
adaptor protein Lnk. While ROS regulated the activity of
these phosphatases, ROS control Lnk through modulation
of expression of its transcript. Although the exact mechanism
of this control is not known, ROS are known to modulate
the expression and activity of several transcription factors
including the AP1 complex (Thannickal and Fanburg, 2000).
Lnk regulatory regions contain several evolutionarily con-
served AP1 sites, suggesting that ROS might regulate Lnk
expression through modulation of AP1 activity.
Interestingly, it was reported recently, while this paper was
under preparation, that in Drosophila, Lnk negatively regu-
lates lifespan via control of oxidative stress (Slack et al, 2010).
In addition, these studies suggested that dFoxo represses Lnk
expression directly. These findings are consistent with our
results here, given that Lnk functions as a positive regulator
of insulin receptor signalling and PI3-kinase in Drosophila,
in contrast to its roles in mammals (Werz et al, 2009).
The high sensitivity of AKT and mTOR phosphorylation
(Figure 4) in Foxo3/ myeloid progenitor compartment to
the administration of anti-oxidants (Figures 5–6) suggests
that the expansion of this population is by AKT/
mTOR amplification and is mediated by ROS. ROS-mediated
amplification of mTOR signalling pathway is consistent
with the redox modulation of the interaction of mTOR with
its regulator raptor (Sarbassov and Sabatini, 2005) and
its repression of oxidative stress in hematopoietic cells
(Chen et al, 2008). Collectively, these findings strongly
suggest that loss of Foxo3 amplifies ROS-mediated cytokine
signalling, in particular AKT/mTOR signalling pathway,
in primitive myeloid progenitor cells in vivo. Importantly,
the short period of anti-oxidant treatments in all these
experiments (Figures 4–6, 8) strongly suggests that a hemato-
poietic stem cell effect is unlikely.
AKT protein kinases are frequently activated in a broad
array of tumours, including haematological malignancies
(reviewed in Bellacosa et al, 2005; Bhaskar and Hay, 2007;
Manning and Cantley, 2007). Here, we found a specific over-
activation of AKT/mTOR signalling in response to cytokines
that contributes significantly to the enhanced generation
of primitive myeloid progenitors in Foxo3-deficient mice
(Figures 3–6). In contrast to the overactivation of AKT/
mTOR signalling, we did not detect any significant increase
in phosphorylation of STAT5 (Ser 726 or Tyr 694), another
major target of cytokine signalling, in response to cytokines
in Foxo3-mutant cells (Figure 4A). One potential explanation
might be that STAT5 follows a distinct phosphorylation
kinetic in wild-type lineage-negative bone marrow cells, as
compared with AKT or mTOR.
The phenotype in Foxo3/ mice resembles human
myeloproliferative disorders that include chronic myeloid
leukemia (CML), polycythemia vera, essential thrombocythemia
and primary myelofibrosis. Constitutive suppression of Foxo3
is critical for growth and survival of cells transformed by
BCR-ABL, the key mediator of CML pathogenesis (Ghaffari
et al, 2003; Komatsu et al, 2003). Our present findings
support the notion that constitutive suppression of Foxo3
activity by oncoproteins in myeloproliferative disorders such
as by BCR-ABL in CML (Ghaffari et al, 2003; Komatsu et al,
2003; Naka et al, 2010) or, potentially, by JAK2V617F in
polycythemia vera, may be a significant contributor to the
pathogenesis of these disorders. In addition, our results in
Foxo3-deficient mice recapitulate the myeloproliferative phe-
notype of the triple Foxo-deficient mice (Tothova et al, 2007).
Together, these findings indicate that Foxo3 is the principal
FoxO operating in hematopoietic stem, as we and others have
previously reported (Miyamoto et al, 2007, 2008; Yalcin et al,
2008), and in progenitor cells, as shown in this study, and
have an essential non-redundant function in hematopoietic
homoeostasis. In agreement with this, Foxo3 was recently
shown to be critical for the maintenance of leukaemic stem
cells in CML (Naka et al, 2010). Despite similarities in our
findings, there are few distinctions between our results and
that of Miyamoto et al (2007) on Foxo3 regulation of
hematopoietic stem and progenitor cells, including lack of
Foxo3/ myeloproliferation in Miyamoto et al’s report.
These discrepancies are likely due to distinct mouse strains
used. As previously reported (Dejean et al, 2009), loss of
Foxo3 did not lead to lymphoproliferation at the steady state
(Table I, Figure 1 and Supplementary Figures 1 and 10),
suggesting that the lymphoproliferative phenotype observed
in Foxo3 gene-trap mice (Lin et al, 2004) might be due to the
strategy or, as has been previously suggested (Dejean et al,
2009) to the mixed strain used to generate these mice.
On the basis of these results, we propose a working model
that postulates that, in contrast to hematopoietic stem cells in
which Foxo3 is constitutively active (Yamazaki et al, 2006;
Yalcin et al, 2008), in HPs transcriptional activity and nuclear
localization of Foxo3 are modulated by cytokine signalling
and ROS. In turn, Foxo3 balances the regulation of cytokine
signalling and ROS (see Figure 10). This model projects that
ROS amplification of cytokine signalling participates in the
activation of HP cells, producing more ROS that will mobilize
Foxo3/ myeloproliferation by ROS via AKT/mTOR
S Yalcin et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 24 | 2010 4127
Foxo3 to the nucleus once accumulated above a certain
threshold. Indeed, it is known that ROS accumulation stimu-
lates nuclear localization of FoxO via activation of multiple
kinases (Greer and Brunet, 2008). Thus, according to this
model, nuclear Foxo3 will in turn suppress ROS and/or
induce apoptosis/cell cycle arrest in the progenitor popula-
tion to maintain hematopoietic homeostasis.
Our combined results indicate that abnormal expression of
Lnk coupled with accumulation of ROS leads to amplified
cytokine signalling, in particular AKT/mTOR signalling path-
way, and altered hematopoietic homeostasis in Foxo3/
mice. Thus, modulations of ROS accumulation significantly
amplify alterations of cytokine signalling and may lead to
malignancies. These findings may be critical in understand-
ing the role of anti-oxidant pathways in promoting
malignancies and cellular aging.
Materials and methods
Mice
The generation and genotyping of mice were performed as
previously described (Castrillon et al, 2003). Progenies, aged 8–12
weeks, of Foxo3þ / mice (129 FBV/n) backcrossed to FVB/n
were intercrossed with littermates to generate the experimental
cohort (F6). In transplantation experiments, Foxo3þ / mice
backcrossed 10 generations onto C57BL6 were used. Wild-type
littermates were used as controls in all experiments. Protocols were
approved by the Institutional Animal Care and Use Committee of
Mount Sinai School of Medicine.
Cells
Blood samples were collected and lineage-negative cells were
separated using a mouse progenitor cell enrichment kit (StemCell
Technologies, Canada), as previously described (Marinkovic et al,
2007; Yalcin et al, 2008). Bone marrow mononuclear cells were
isolated using lympholyte M density separation medium according
to manufacturer’s protocol (Cederlane, Hornby, Ontario, Canada).
In vitro clonogenic progenitor assay
Myeloid clonogenic assays were performed as previously described
(Ghaffari et al, 2006; Zhao et al, 2006; Yalcin et al, 2008). Cells
(5106 peripheral blood, 5105 spleen and 3104 bone marrow
cells) were cultured in MethoCult 3234 (StemCell Technologies)
containing 50 ng/ml rat stem cell factor (SCF), 10 ng/ml IL6,
10 ng/ml IL3 and 3 U/ml Epo (all from PeproTech EC, Rocky Hill,
NJ, USA). Colonies were counted after 8–10 days.
Colony-forming unit spleen assay day 12
Bone marrow (1105) cells from 8 to 10-week-old wild-type or
Foxo3/ littermates or GFP-positive transduced cells were isolated
and intravenously injected into recipient C57BL6 mice (Charles
River Laboratory) previously subjected to 10 Gy irradiation.
Recipient spleens were excised 12 days later, fixed in Telleyesnicz-
ky’s solution and macroscopic spleen colonies were counted as
described (Till and Mc, 1961).
Flow cytometry and cell sorting
Antibody staining and flow cytometry analysis were previously
described (Marinkovic et al, 2007; Yalcin et al, 2008). For CMP
isolation (Lin IL-7Ra Sca-1 c-Kitþ FcgRlowCD34þ ) (Akashi
et al, 2000), cells were stained with anti-c-Kit (BD Biosciences),
anti-FcR (eBioscience) and anti-CD34 (eBioscience) antibodies
directly conjugated with fluorescein isothiocyanate, phycoerythrin
or allophycocyanin, and with biotinylated multi-lineage monoclonal
antibody cocktail (StemCell Technologies) as well as biotinylated
antibodies against IL-7R (eBioscience) and Sca-1 (BD Biosciences)
visualized with PECyc7-Streptavidin or Pacific Blue-Streptavidin.
To measure intracellular AKT phosphorylation, Lin IL7-Ra
Sca-1 c-Kitþ cells were fixed with fix/permeabilization buffer (BD
Biosciences) and incubated with 1:50 dilution of anti-pSer473 AKT
antibody (Cell Signaling Technology). To measure protein phos-
phorylation in response to Lnk expression, transduced cells were
starved in vitro in Iscove’s modified Dulbecco’s medium (IMDM)
with 0.1% FCS for 2 h, stimulated with IL-3 (10 ng/ml) and fixed,
and optimum phosphorylation was detected by flow cytometry (15
and 45 min for pmTOR/pS6 and pAKT, respectively). Cells were
incubated with 1:100 dilution of anti-pSer473 AKT, pSer2448 mTOR
and pSer235/236 S6 antibodies (Cell Signaling Technology).
Samples were washed and protein phosphorylation was analysed
in GFPþ -gated cells by flow cytometry.
Cell proliferation and apoptosis assays
Mice were injected intravenously with 2 mg of BrdU. At 19 h post
injection, bone marrow Lin IL7Ra Sca-1 c-Kitþ cells were fixed
and stained with anti-BrdU antibody (BD Biosciences) for flow
cytometric analysis of cell proliferation.
Freshly isolated Lin IL7Ra Sca-1 c-Kitþ cells were assayed






















Figure 10 Model for Foxo3 regulation of hematopoietic progenitor cell activity. In hematopoietic progenitors, cytokine receptor signalling
generates ROS that further activate receptor signalling (AKT/mTOR), leading to cell proliferation, increased production of ROS and ultimate
induction of Foxo3 nuclear localization once ROS are accumulated above certain threshold. Signalling is modulated by cytokine receptor
regulators including Lnk, a negative regulator. In Foxo3/ hematopoietic progenitors, decreased expression of Lnk, associated with significant
increase in ROS accumulation, enhance cytokine-mediated signalling, leading to myeloproliferation.
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Measurement of intracellular ROS
ROS were measured as previously described (Marinkovic et al,
2007; Yalcin et al, 2008).
RNA isolation and QRT–PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen). First-strand
cDNA was synthesized using SuperScript (Invitrogen). Quantitative
RT–PCR was performed using SYBR Green JumpStart Taq ReadyMix
(Takara) in duplicates using ABI Prism 7900 HT Cycler (Applied
Biosystems). Gene-specific primers spanning intron–exon boundary
were designed by Primer Express 2.0 (ABI) and subjected to BLAST
analysis to ensure the primer specificity. The PCR cycle parameters
were as follows: 951C for 1000 followed by 45 cycles at 951C for 500,
601C for 3400 and 721C for 3000. Relative quantification was achieved
using the sequence detection system software (Applied Biosystems)
and a fractional cycle number at which threshold fluorescence was
obtained (threshold cycle, CT); for each analysis, comparative CT
method for quantification of the target genes relative to b-actin as
the reference was used. Results shown as fold change are relative to
wild type controls. Primer sequences are listed in Supplementary
Table 1.
Western blot analysis
Freshly isolated lineage-negative bone marrow cells were starved
in vitro for 2 h in IMDM with 0.1% FCS and then stimulated with
IL-3 (20 ng/ml) for the indicated time points. Cells were harvested
and lysates were prepared in 1 RIPA lysis buffer (20 mM sodium
phosphate, 300 mM sodium chloride, 4 mM EDTA) containing 2%
sodium deoxycholate, 2% NP-40, 0.2% SDS, 400mM sodium
orthovanadate, 0.2% b-mercaptoethanol, 2 mM PMSF and 100 mM
sodium fluoride and protease cocktail inhibitors (Roche). Samples
were run on SDS–PAGE, blotted and probed with following
antibodies at 1:1000 dilutions: anti-pSer473 AKT, anti-AKT, anti-
pThr389 S6Kinase, anti-S6Kinase, anti-pSer2448 mTOR, anti-mTOR
and anti-pTyr694 STAT5 (all from Cell Signaling Technology) and
anti-Lnk (M-20; Santa Cruz). Anti-pSer726 STAT5 (Upstate Bio-
technology) and anti-STAT5 (BD Biosciences) were used at final
concentrations of 1:500 and 1:200, respectively.
Histology
Spleen and liver tissues from 11-week-old wild-type or FoxO3/
littermates were collected and paraffin embedded after 10%
formalin fixation. Sections (8–10 mm) were stained with hematox-
ylin and eosin for histology analysis.
In vivo treatment with N-acetyl-L-cysteine or rapamycin
Mice received intraperitoneal administration of 100 mg/kg of body
weight NAC (Sigma, St. Louis, MO, USA) in PBS (pH 7.4) for the
indicated time period, as previously described (Yalcin et al, 2008).
Cultured cells were incubated with NAC (100 mM) for the indicated
time period. Rapamycin (Sigma) was administrated intraperitone-
ally (4 mg/kg in PBS containing 5% Tween 80, 5% PEG 400 and 4%
ethanol) for 5 days a week (Yilmaz et al, 2006).
For in vitro rapamycin treatment, total bone marrow cells
isolated from wild-type and Foxo3/ mice were cultured with
rapamycin (final concentration 2 mM) or vehicle for 24 h after which
mRNA was isolated for QRT–PCR analysis.
Retroviral production and transduction of 5-FU-treated bone
marrow mononuclear cells
Retroviral supernatants were produced as previously described
(Zhao et al, 2006). Bone marrow mononuclear cells isolated from
mice treated 4 days previously with 5-FU (150 mg/kg, Sigma) were
pre-stimulated for 2 days in IMDM containing 15% heat-inactivated
FCS supplemented with IL-6 (10 ng/ml), IL-3 (6 ng/ml) and SCF
(100 ng/ml; PeproTech EC), after which cells were resuspended in
retroviral supernatants (multiplicity of infection of 10) for 2
consecutive days and plated on retronectin-coated dishes in
IMDM–15% FCS containing the same factors. At 48 h after
initiation, live GFP-positive cells were FACS sorted and used for
experiments.
Statistical analysis
The unpaired two-tail Student’s t-test was used for all experiments.
A P-value of o0.05 was considered to be significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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